African Americans (AAs) are more likely to develop and die from cancer than any racial and ethnic group in the United States (U.S.). Over the past two decades, there has been an increased focus on participation of AAs in cancer clinical trials (CCTs) to address this disproportionate burden of cancer; however AAs continue to be underrepresented in CCTs. The dearth of AAs participating in CCTs diminishes the generalizability of results of trials. If AAs remain underrepresented in CCTs, the implications include slower progress in elucidating the underlying causes of long-standing health disparities in cancer outcomes. There is an extensive body of science detailing trial participation barriers among AAs, including limited access to specialty care centers where trials are conducted, competing work obligations, and fear and mistrust of clinical research. Despite these barriers, AAs are, inherently, no less willing to participate in CCTs or other types of research studies than other racial or ethnic groups. The absence of differences in willingness to participate suggests that persistent disparities in accrual may, in fact, be due to AAs being offered fewer opportunities than whites to participate in CCTs. Although many interventions have focused on approaches to increase the willingness of AAs to participate, perhaps efforts should be focused on increasing the opportunities among AAs to participate in CCTs. We propose to adapt the IMPaCT patient navigation model and pilot a clinical trials navigator program, IMPaCT 2.0, at Morehouse Healthcare (MH) and Grady Hospital (Grady), one of the largest safety-net hospitals in the nation. We propose to enhance the patient navigation model with a mobile tablet-based clinical trial tracking system (CTTS) (using i2b2 software) to facilitate increased engagement among AA patients regarding CCT participation opportunities and to address deficits in the research infrastructure at these two institutions. Utilizing a qualitative approach, we will identify those barriers and facilitators to AA recruitment at MH/Grady (Specific Aim 1) and incorporate those findings into an adapted clinical trials navigation (CTN) model with an integrated mobile tablet CTTS (Specific Aim 2)., We will implement IMPaCT 2.0 at MH/Grady breast and prostate cancer clinics and evaluate, in a one-group, pre-/post-test design, the feasibility and acceptability (Specific Aim 3).

Public Health Relevance

This Pilot Project proposes to adapt the IMPaCT patient navigation model and pilot a clinical trials navigator program, at Morehouse Healthcare (MH) and Grady Hospital (Grady), one of the largest safety-net hospitals in the nation. We propose to enhance the patient navigation model with a mobile tablet-based clinical trial tracking system (CTTS) (using i2b2 software) to facilitate increased engagement among AA patients regarding CCT participation opportunities and to address deficits in the research infrastructure at these two institutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA118638-15
Application #
10007641
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2005-09-30
Project End
2021-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
15
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Morehouse School of Medicine
Department
Type
DUNS #
102005451
City
Atlanta
State
GA
Country
United States
Zip Code
30310
Akintobi, Tabia Henry; Lockamy, Elise; Goodin, Lisa et al. (2018) Processes and Outcomes of a Community-Based Participatory Research-Driven Health Needs Assessment: A Tool for Moving Health Disparity Reporting to Evidence-Based Action. Prog Community Health Partnersh 12:139-147
Luo, Yanzhuo; Li, Bingjin; Zhang, Guangxin et al. (2018) Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without EGFR Mutations or ALK Fusion. J Cancer 9:1096-1105
Sims, Alexis; Archie-Booker, Elaine; Waldrop, Reinetta T et al. (2018) Factors Associated with Human Papillomavirus Vaccination among Women in the United States. ARC J Public Health Community Med 3:6-12
Davis, Melissa; Tripathi, Shweta; Hughley, Raymond et al. (2018) AR negative triple negative or ""quadruple negative"" breast cancers in African American women have an enriched basal and immune signature. PLoS One 13:e0196909
Ward, Ashley B; Mir, Hina; Kapur, Neeraj et al. (2018) Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways. World J Surg Oncol 16:108
Singh, Santosh Kumar; Mishra, Manoj K; Eltoum, Isam-Eldin A et al. (2018) CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci Rep 8:1323
Puri, Pawan; Schaefer, Caitlin M; Bushnell, Daniel et al. (2018) Ectopic Phosphorylated Creb Marks Dedifferentiated Proximal Tubules in Cystic Kidney Disease. Am J Pathol 188:84-94
Nguyen, Thu-Cuc; Bajwa, Ravneet; Bari, Shahla et al. (2018) Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer. Oxf Med Case Reports 2018:omx078
Akinyemiju, Tomi; Moore, Justin Xavier; Pisu, Maria et al. (2018) A Prospective Study of Obesity, Metabolic Health, and Cancer Mortality. Obesity (Silver Spring) 26:193-201
Chowdhury, Indrajit; Banerjee, Saswati; Driss, Adel et al. (2018) Curcumin attenuates proangiogenic and proinflammatory factors in human eutopic endometrial stromal cells through the NF-?B signaling pathway. J Cell Physiol :

Showing the most recent 10 out of 114 publications